Table 2.

Clinical, epidemiological, microbiological, and therapeutic responses in patients with pediatric sporotrichosis observed in recent case series from Mexico and Brazil

Country	Age years old n (range)	Gender n (%)	Suspected source of infection n (%)	Clinical form n (%)	Anatomical site n (%)	Evidence level of diagnosis n (%)	Therapy N (%)	Time of therapy (months)	Clinical response N (%)
Mexico	10.4 (4–17)	Male 12 (60) Female 8 (40)	Trauma either at school or with vegetation 12 (60) Squirrel scratch 2 (10) Contact with corn leaves 2 (10) Unknown 4 (20)	Lymphocutaneous 13 (65%) 30% fixed cutaneous 6 (30) Disseminated 1 (5%)	Upper limbs 12 (60) Face 6 (30) 5% upper limb + face (n = 1) 5% lower limbs (n = 1)	95% proved Sporothrix schenkii (n = 19) 5% proved Sporothrix globose (n = 1)	35% itraconazole (n = 7) 55% potassium iodide (n = 11) 5% potassium iodide + thermotherapy (n = 1) 5% thermotherapy (n = 1)	Mean 3.5 months (95% CI 2.9 to 4.0)	85% cure (n = 17) 10% improved (n = 2) 5% unkown (n = 1)
Brazil	9.9 (1–17)	Female 12 (60) Male 8 (40)	Cat contact 20 (100)	50% lymphocutaneous 10 (50%) Cutaneous 5 (25%) Ocular 5 (25%) ocular + lymphocutaneous or cutaneous	45% face (n = 9) 30% upper limb (n = 6) 10% lower member + face (n = 2) 10% lower member (n = 2) 5% lower member + face + upper limb (n = 1)	35% proved* Sporothrix brasiliensis (n = 7) 65% probable** Sporothrix brasiliensis (n = 13)	100% itraconazole (n = 20)	Mean 3.6 months (95% CI 3.1 to 4.2)	95% cure (n = 1) 5% improved (treatment ongoing) (n = 1)

^**Criteria from the Guide to Health Surveillance, 5ª Ed. Ministry of Health, Brazil, 2021 Ref 69